Sponsor

Astellas Pharma Korea, Inc.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Astellas Pharma Korea, Inc. appears in 12 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials12
Recruiting shown0
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

12 shown
Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer PatientsNCT06452212 · lead sponsor · 2024-07-10
COMPLETED
A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)NCT03737708 · lead sponsor · 2019-02-13
COMPLETED
A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With AlbuminuriaNCT03118713 · lead sponsor · 2017-04-25
TERMINATED
A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and SitagliptinNCT02452632 · lead sponsor · 2015-06-22
COMPLETED
Study to Evaluate the Safety and Efficacy of Advagraf vs Prograf in Kidney Transplantation Patients 1 Month After the TransplantationNCT01742624 · lead sponsor · 2012-04-01
COMPLETED
Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and MetforminNCT03076112 · collaborator · 2017-04-25
COMPLETED
Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With IpragliflozinNCT02791035 · collaborator · 2016-06-01
COMPLETED
Beraprost Sodium and Arterial Stiffness in Patients With Type 2 Diabetic NephropathyNCT01796418 · collaborator · 2013-03-01
UNKNOWN
A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)NCT01511003 · collaborator · 2011-12-05
COMPLETED
The Effect of Prostaglandin I2 on the Endothelial Cell Function Disorder in Type 2 Diabetes Mellitus PatientsNCT01061060 · collaborator · 2010-01-01
COMPLETED
Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to MethotrexateNCT01224041 · collaborator · 2009-08-01
COMPLETED
A Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to MethotrexateNCT01224418 · collaborator · 2008-05-01
COMPLETED

Drugs studied in this sponsor's trials

9 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Astellas Pharma Korea, Inc. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
tacrolimus4
placebo2
epoprostenol1
glimepiride1
metformin1
methotrexate1
mycophenolate mofetil1
Prograf1

Sponsor roles

collaborator7
lead sponsor5
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.